Stock Research Monitor: ILMN, NXTM, and SIEN

LONDON, UK / ACCESSWIRE / May 22, 2018 / If you want a free Stock Review on VLRX sign up now at www.wallstequities.com/registration. For today, WallStEquities.com features the following Medical Instruments and Supplies companies: Illumina Inc. (NASDAQ: ILMN), Nxstage Medical Inc. (NASDAQ: NXTM), Sientra Inc. (NASDAQ: SIEN), and Valeritas Holdings Inc. (NASDAQ: VLRX). The Medical Instrument and Supply Manufacturing industry primarily researches, develops, and produces nonelectronic medical, surgical, dental, and veterinary instruments and apparatus. All you have to do is sign up today for this free limited time offer by clicking the link below.

www.wallstequities.com/registration

Illumina

On Monday, shares in San Diego, California headquartered Illumina Inc. recorded a trading volume of 508,467 shares. The stock ended at $268.29, declining slightly by 0.51% from the last trading session. The Company's shares have gained 9.69% in the last month, 18.41% over the previous three months, and 51.57% over the past year. The stock is trading above its 50-day and 200-day moving averages by 8.74% and 20.40%, respectively. Furthermore, shares of Illumina, which provides sequencing and array-based solutions for genetic analysis, have a Relative Strength Index (RSI) of 64.09.

On May 15th, 2018, Illumina announced that it acquired Edico Genome, the leading provider of data analysis acceleration solutions for next-generation sequencing. Edico Genome's DRAGEN® Bio-IT Platform uses field programmable gate array technology, in conjunction with proprietary software algorithms, to reduce both data footprint and time to results. The DRAGEN platform complements ILMN's sequencing portfolio and enables customers to benefit from reduced investment in compute infrastructure and accelerated result times to improve their overall efficiency and to allow greater emphasis on interpretation and reporting. Get the full research report on ILMN for free by clicking below at:

www.wallstequities.com/registration/?symbol=ILMN

Nxstage Medical

Lawrence, Massachusetts headquartered Nxstage Medical Inc.'s stock finished yesterday's session 0.53% higher at $26.59. A total volume of 531,337 shares was traded, which was above their three months average volume of 530,690 shares. The Company's shares have gained 4.27% in the last month, 8.44% over the previous three months, and 24.25% over the past year. The stock is trading above its 50-day and 200-day moving averages by 4.31% and 2.25%, respectively. Furthermore, shares of Nxstage Medical, which develops, manufactures, and markets products and services for patients suffering from chronic or acute kidney failure, have an RSI of 59.44. The free technical report on NXTM can be accessed at:

www.wallstequities.com/registration/?symbol=NXTM

Sientra

At the close of trading on Monday, shares in Santa Barbara, California headquartered Sientra Inc. rose 1.71%, ending the day at $17.27. The stock recorded a trading volume of 318,134 shares. The Company's shares have advanced 34.50% in the last month, 54.06% in the previous three months, and 127.84% over the past year. The stock is trading 42.21% and 35.17% above its 50-day and 200-day moving averages, respectively. Moreover, shares of Sientra, which develops and sells medical aesthetics products to plastic surgeons in the US, have an RSI of 75.92.

On April 27th, 2018, research firm Lake Street upgraded the Company's stock rating from ?Hold' to ?Buy', with a target price of $16 per share.

On May 07th, 2018, Sientra announced the closing of its previously announced underwritten public offering of 7,407,408 shares of the Company's common stock, as well as 1,111,111 additional shares of its common stock pursuant to the full exercise of the over-allotment option granted to the underwriters. All of the shares were sold by the Company. Sign up for free on Wall St. Equities and claim the latest report on SIEN at:

www.wallstequities.com/registration/?symbol=SIEN

Valeritas Holdings

Bridgewater, New Jersey headquartered Valeritas Holdings Inc.'s shares ended the day 1.26% lower at $1.57. A total volume of 1.18 million shares was traded, which was above their three months average volume of 667,390 shares. The stock is trading 28.84% below its 50-day moving average. Additionally, shares of Valeritas, which focuses on the development and commercialization of technologies to treat patients with Type 2 diabetes in the US and China, have an RSI of 42.35.

On May 21st, 2018, Valeritas announced that it signed an exclusive distribution agreement with MED TRUST for the commercialization of its V-Go® Wearable Insulin Delivery device in Austria and Germany. Under the terms of the agreement, MED TRUST will have the rights to promote, market, and sell the V-Go to diabetes clinics and patients in Austria and Germany. See the free research coverage on VLRX at:

www.wallstequities.com/registration/?symbol=VLRX

Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

WSE has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

https://wallstequities.com/legal-disclaimer/

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@wallstequities.com

Phone number: 21 32 044 483

Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Wall St. Equities